Clinical Trial Update: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial results for ANK-700 in relapsing-remitting multiple sclerosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• ANK-700

Snippet

Sponsor: Anokion SA | Conditions: Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis | Phase 1 | Status: COMPLETED | Results posted: 2025-05-31